Synthetic Biologics Inc., of Rockville, Md., said it closed its public offering for gross proceeds of about $18.6 million. Funds will be used for preclinical and clinical programs and for working capital and general corporate purposes, including to acquire, license or invest in complementary businesses, technologies, product candidates or other intellectual property.